What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Program Goals
Program Overview
Intensifying Diabetes Therapy In Patients Already On Basal Insulin: Challenge
"Maximum" Dose of Basal Insulin
Combination Injectable Therapy: Evidence-Based Recommendations
Time From Initiation of Basal Insulin to Intensification in Clinically Eligible Patients*
Treatment for Hyperglycemia Changes Over Time in Patients With T2DM
"Maximum" Dose of Basal Insulin (cont)
Achieving Glycemic Control
Relative Contributions of FPG and PPG to HbA1c
Basal Insulin/GLP-1 RA FRC Agents
LixiLan-L Trial: Key Results
DUAL V: Key Results
CVOTs With GLP-1 RAs
Mechanism of Action of GLP-1 RAs
Nutrition Therapy in Patients With T2DM
Benefits of Adding a GLP-1 RA to Basal Insulin vs Adding Prandial Insulin
Cost-Effectiveness of FRC Therapy: Data From DUAL V
Integrating Basal Insulin/GLP-1 RA FRC Therapy Into Primary Care: Challenges
Basal Insulin/GLP-1 RA FRC Agents
Integrating Basal Insulin/GLP-1 RA FRC Therapy Into Primary Care: Challenges (cont)
Mean Daily Dose of Basal Insulin Significantly Lower With FRC Therapy
Fewer Adverse GI Events With FRC Agents vs GLP-1 RAs
Basal Insulin/GLP-1 RA FRC Agents: Available in Prefilled Pens
Minimizing the Risk of Nausea When Adding a GLP-1 RA to Basal Insulin
Understanding the Role of Basal Insulin/GLP-1 RA FRC Agents In T2DM Management
Using Basal Insulin/GLP-1 RA FRC Therapy in Clinical Practice -- IDegLira
Using Basal Insulin/GLP-1 RA FRC Therapy in Clinical Practice -- IGlarLixi
Switching to Basal Insulin/GLP-1 RA FRC Therapy: Practical Considerations
Switching to Basal Insulin/GLP-1 RA FRC Therapy: Practical Considerations (cont)
IGlarLixi: Method of Administration
Insulin Dose
Basal Insulin/GLP-1 RA FRC Therapy: Future Considerations
Summary
Abbreviations